Scientific Publications

Advancing dermatological science.

September 2021 Featured

EADV 2021

Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients with Chronic Plaque Psoriasis (DERMIS-1 and DERMIS-2)

July 2020 Featured

New England Journal of Medicine

Trial of Roflumilast Cream for Chronic Plaque Psoriasis

September 2021

EADV 2021

Roflumilast Cream 0.3%, Safety and Efficacy in Patients with Chronic Plaque Psoriasis (DERMIS-1 and DERMIS-2)

September 2021

EADV 2021

Roflumilast Foam 0.3% Improved the Severity and Burden of Itch in Patients with Scalp and Body Psoriasis

September 2021

EADV 2021

Roflumilast Foam 0.3%, Safety and Efficacy in Patients with Seborrheic Dermatitis

July 2021

Dermatology and Therapy

Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score

May 2021

EADV Spring Symposium 2021

Roflumilast Cream, Safety and Efficacy in two Ph3 Studies (DERMIS-1 and DERMIS-2) in Patients with Chronic Plaque Psoriasis

April 2021

AAD 2021

Roflumilast Cream, Correlation of Itch and Disease Severity in Adults with Chronic Plaque Psoriasis, Ph2b Study

April 2021

AAD 2021

Roflumilast Foam, Safety and Efficacy in Patients with Scalp and Body Psoriasis, Ph2b Study

April 2021

AAD 2021

Roflumilast Foam, Safety and Efficacy in Patients with Seborrheic Dermatitis, Ph2 Study

April 2021

AAD 2021

Roflumilast Cream, Safety and Efficacy in Steroid-sensitive Areas in Adults with Chronic Plaque Psoriasis, Ph2b Study

April 2021

AAD 2021

PASI-HD Improved Precision in Measuring Disease Severity in Patients with Mild to Moderate Plaque Psoriasis Treated with Roflumilast Cream, Ph2b Study

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download